Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02151539 · ClinicalTrials.gov registry record

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.

Terminated
Registry status
19
Enrollment target

NCT02151539 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02151539 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.

TERMINATED
Registry status
19 participants
Enrollment target

Study Summary

This research trial studies medical chart review in determining outcomes of second-line therapy in patients with acute graft-versus-host disease previously treated with extracorporeal photopheresis or other systemic therapies. Gathering information about second-line therapy in patients with acute graft-versus-host disease may help doctors learn more about the disease and find better treatment.

Interventions

  • OTHER medical chart review
  • OTHER quality-of-life assessment

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2014-08-29
Est. Completion 2018-10-11

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

What the Registry Record Tells You About NCT02151539

The ClinicalTrials.gov registry entry for NCT02151539 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which medical chart review is the first listed.

NCT02151539 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02151539 about?

NCT02151539 is a clinical study titled "Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)". This research trial studies medical chart review in determining outcomes of second-line therapy in patients with acute graft-versus-host disease previously treated with extracorporeal photopheresis or other systemic therapies. Gathering information about second-line therapy in patients with acute gr...

What is the current status of trial NCT02151539?

This trial is currently terminated. The enrollment target is 19 participants. The study started on 2014-08-29. Estimated completion is 2018-10-11.

What interventions are being tested in trial NCT02151539?

The interventions under investigation include: medical chart review (OTHER), quality-of-life assessment (OTHER).

Who is sponsoring clinical trial NCT02151539?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.